Diversity Management, News and Updates
Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in…
On World Hypertension Day 2017, the Novartis Foundation and its partners, including Intel Corporation, the NCD Alliance, city governments and local partners, announce the launch of Better Hearts Better Cities, an innovative initiative to address the high rates of high blood pressure (hypertension) in low-income urban communities. Rapid urbanization in…
Novartis (No. 2 on the DiversityInc Top 50 Companies list) isproud of the passion of itspeople and their dedication to the fight against malaria.
Dr. Vas Narasimhan The Novartis Foundation (No. 2 on the DiversityInc Top 50 Companies list) announced on March 23 that Vasant (Vas) Narasimhan, M.D., joined its Board of Trustees in January. He replaces Rainer Boehm, who stepped down from the Board upon his retirement as Chief Commercial and Medical Affairs…
Novartis (No. 2 on the DiversityInc Top 50 Companies list) has announced a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as…
Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3 percent compared to placebo (1.63 vs 2.98, p=0.010) in patients with or without hydroxyurea therapy1. Novartis (No. 2 on the DiversityInc…
Novartis (No. 2 on the DiversityInc Top 50 Companies list) announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating…
In a remote village in Thailand, on the border of Myanmar (formerly Burma), Novartis (No. 2 on the DiversityInc Top 50 Companies list) researchers completed an early-phase clinical trial of an experimental treatment for malaria. The team overcame floods that swamped the facility an open-air structure with wooden beds and…
The joint dialogue event is co-hosted by Novartis Access and the Novartis Foundation, with experts from Novartis (No. 2 on the DiversityInc Top 50 Companies list), academia and nonprofit organizations speaking and attending. It will be an opportunity to look back on the lessons learned during the first year of…
In the 10 years Zhang Bin has been an ophthalmologist, he’s performed hundreds of cataract surgeries. Yet he saw there was still tremendous need for improved access to eye care among the 8 million people living in and around Shenyang, where some of his patients travel three hours for treatment….
